ReviewGenes & diseases2024
Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology.
Review in Genes & diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- [Analysis of cardiovascular adverse events associated with 8 immune checkpoint inhibitors based on the FAERS database].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026Article
- Recent research progress and clinical status of immunotherapy for colorectal cancer.Journal of advanced research · 2026Review
- The Impact of Immune-Related Adverse Events on the Survival of Patients Treated with Immune Checkpoint Inhibitors: The Distinct Role of Cardiac Toxicities.Journal of clinical medicine · 2025Article
- Cardio-Oncology and Breast Cancer Therapies.Current treatment options in oncology · 2025Review
- Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.Frontiers in immunology · 2025Article
- Incidence and risk assessment of thyroid dysfunction following immune checkpoint inhibitor therapy: a systematic review and meta-analysis.American journal of translational research · 2025Article
- Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System.Therapeutic advances in drug safety · 2025Article
- Article
- Prognostic significance and immune landscape of a cell cycle progression-related risk model in bladder cancer.Discover oncology · 2024Article
- Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome.Life (Basel, Switzerland) · 2024Article
- Review
- Integrating necroptosis into pan-cancer immunotherapy: a new era of personalized treatment.Frontiers in immunology · 2024Article
- Comprehensive pan‑cancer analysis of potassium voltage-gated channel Q4 (KCNQ4) gene across multiple human malignant tumors.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are monoclonal antibody antagonists, which can block cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed death-1/ligand-1 (PD-1/PD-L1) pathways, and other molecules exploited by tumor cells to evade T cell-mediated immune response. ICIs have transformed the treatment landscape for various cancers due to their amazing efficacy. Many anti-tumor therapies, including targeted therapy, radiotherapy, and chemotherapy, combine ICIs to make the treatment more effective. However, the off-target immune activation caused by ICIs may lead to a broad spectrum of immune-related adverse events (irAEs) affecting multiple organ systems. Among irAEs, cardiotoxicity induced by ICIs, uncommon but fatal, has greatly offset survival benefits from ICIs, which is heartbreaking for both patients and clinicians. Consequently, such cardiotoxicity requires special vigilance, and it has become a common challenge both for patients and clinicians. This article reviewed the clinical manifestations and influence of cardiotoxicity from the view of patients and clinicians, elaborated on the underlying mechanisms in conjunction with animal studies, and then attempted to propose management strategies from a cardio-immuno-oncology multidisciplinary perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.